Chemours Co

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

CC$13.28+4.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Interim Consolidated Balance Sheets (Unaudited)

	September 30, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$698	$670
Restricted cash and restricted cash equivalents	41	2
Accounts and notes receivable, net	922	679
Inventories	1,475	1,569
Prepaid expenses and other	82	80
Assets held for sale	1	1
Total current assets	3,219	3,001
Property, plant, and equipment	9,996	9,920
Less: Accumulated depreciation	(6,992)	(6,842)
Property, plant, and equipment, net	3,004	3,078
Operating lease right-of-use assets	282	271
Goodwill	46	46
Other intangible assets, net	2	2
Investments in affiliates	184	160
Assets held for sale, non-current	—	21
Restricted cash and restricted cash equivalents	62	52
Other assets	494	751
Total assets	$7,293	$7,382
Liabilities
Current liabilities:
Accounts payable	$995	$954
Compensation and other employee-related cost	87	96
Short-term and current maturities of long-term debt	50	42
Current environmental remediation	116	88
Other accrued liabilities	529	506
Total current liabilities	1,777	1,686
Long-term debt, net	3,783	4,099
Operating lease liabilities	192	191
Long-term environmental remediation	689	530
Deferred income taxes	65	37
Other liabilities	631	588
Total liabilities	7,137	7,131
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 199,333,095 shares issued and 150,519,801 shares outstanding at September 30, 2026; 198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025)	2	2
Treasury stock, at cost (48,813,294 shares at September 30, 2026 and 48,826,793 at December 31, 2025)	(1,801)	(1,802)
Additional paid-in capital	1,092	1,074
Retained earnings	1,073	1,220
Accumulated other comprehensive loss	(211)	(244)
Total Chemours stockholders’ equity	155	250
Non-controlling interests	1	1
Total equity	156	251
Total liabilities and equity	$7,293	$7,382

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.